

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

ADDITIONAL RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING

This announcement is made by TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcements made by the board (the “**Board**”) of directors (“**Director(s)**”) of the Company dated 2 April 2024, 18 April 2024, 5 June 2024, 27 June 2024, 28 June 2024, 31 July 2024, 30 September 2024, 4 October 2024, 3 January 2025, 31 March 2025, 11 July 2025, 14 July 2025 and 25 July 2025 in relation to, among other things, the resumption guidance and the additional resumption guidance imposed by the Stock Exchange on the Company (the “**Initial Resumption Guidance**”) and quarterly updates on resumption progress (collectively, the “**Resumption Guidance and Quarterly Update Announcements**”); and (ii) the announcement of the Company dated 3 September 2025 in relation to, among others, resignation of Mr. WANG Jian (“**Mr. Wang**”) as an independent non-executive Director (the “**Resignation Announcement**”, together with the Resumption Guidance and Quarterly Update Announcements, collectively, the “**Announcements**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

ADDITIONAL RESUMPTION GUIDANCE

As disclosed in the Resignation Announcement, following the resignation of Mr. Wang as an independent non-executive Director with effect from 3 September 2025, none of the existing independent non-executive Directors possess appropriate professional qualifications or accounting or related financial management expertise as prescribed under Rule 3.10(2) of the Listing Rules. Accordingly, the Company is not in compliance with the requirement under Rule 3.10(2) of the Listing Rules.

On 4 September 2025, the Company received a letter from the Stock Exchange setting out additional guidance for the resumption of trading in the Shares on the Stock Exchange (the “**Additional Resumption Guidance**”, together with the Initial Resumption Guidance, collectively, the “**Resumption Guidance**”):

- re-comply with Rule 3.10(2) of the Listing Rules.

The Stock Exchange requires the Company to remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange’s satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has the primary responsibility to devise its action plan for resumption. The Stock Exchange also indicated that it may modify the Resumption Guidance and/or give further guidance as and when appropriate.

As at the date of this announcement, the Company is still in the process of identifying a suitable candidate so as to fulfill the requirements under Rule 3.10(2) of the Listing Rules, and will endeavour to appoint such candidate as independent non-executive Director as soon as practicable within three months from 3 September 2025. The Company will make further announcement in relation to such appointment as and when appropriate in accordance with the Listing Rules.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024 and will remain suspended pending the fulfilment of the Resumption Guidance. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
TATA Health International Holdings Limited
Zhang Ming Qi
Non-executive Director

Hong Kong, 5 September 2025

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Chu Chun Ho, Dominic, Mr. Zhang Ming Qi and Mr. Chen Qi; and three independent non-executive Directors, namely, Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng.